NCT00291837View on ClinicalTrials.gov

CT-2106 for the Second Line Treatment of Ovarian Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

June 30, 2006

Study Completion Date

December 31, 2007

Conditions

Ovarian Cancer

Interventions

DRUG

CT-2106

Trial Locations (7)

Unknown

Lyon

Saint-Brieuc

Campobasso

Birmingham

London

Newcastle upon Tyne

Surrey

Sponsors

Lead Sponsor

All Listed Sponsors

lead

CTI BioPharma

INDUSTRY